Perspectives for repurposing drugs for the coronavirus disease 2019

The newly emerged 2019 novel coronavirus (CoV), named as severe acute respiratory syndrome CoV-2 (SARS-CoV-2), like SARS-CoV (now, SARS-CoV-1) and Middle East respiratory syndrome CoV (MERS-CoV), has been associated with high infection rates with over 36,405 deaths. In the absence of approved market...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Indian journal of medical research (New Delhi, India : 1994) India : 1994), 2020-02, Vol.151 (2), p.160-171
Hauptverfasser:	Cherian, Sarah, Agrawal, Megha, Basu, Atanu, Abraham, Priya, Gangakhedkar, Raman, Bhargava, Balram
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Betacoronavirus Coronavirus infections Coronavirus Infections - drug therapy Coronaviruses COVID-19 Diseases Drug approval Drug Discovery Drug Repositioning Drugs Health aspects Humans Infection Lopinavir Marketing Middle East respiratory syndrome Molecular Docking Simulation Pandemics Penciclovir Pneumonia, Viral - drug therapy Protease Inhibitors - therapeutic use Review Severe acute respiratory syndrome Time Viral Proteins - antagonists & inhibitors Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!